<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341535</url>
  </required_header>
  <id_info>
    <org_study_id>2010/567</org_study_id>
    <nct_id>NCT01341535</nct_id>
  </id_info>
  <brief_title>Comparison of Adaptive Dose Painting by Numbers With Standard Radiotherapy for Head and Neck Cancer.</brief_title>
  <acronym>C-ART-2</acronym>
  <official_title>A Two-arm Phase II Randomized Study, Comparing Adaptive Biological Imaging - Voxel Intensity - Based Radiotherapy (Adaptive Dose Escalation) Versus Standard Radiotherapy for Head and Neck Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that treatment adaptation to biological and anatomical changes,&#xD;
      occurring during treatment, can increase the chance of cure at minimized or equal&#xD;
      radiation-induced toxicity in head and neck cancer patients. This trial compares standard&#xD;
      intensity-modulated radiotherapy (IMRT), using only pre-treatment planning&#xD;
      18F-2-fluoro-2-deoxy-D-glucose positron emission tomography to adaptive&#xD;
      18F-2-fluoro-2-deoxy-D-glucose positron emission tomography voxel intensity based IMRT or&#xD;
      volumetric-modulated arc therapy (VMAT) using repetitive per-treatment planning&#xD;
      18F-2-fluoro-2-deoxy-D-glucose positron emission tomography for head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2011</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To obtain 25 % increase in local control at 1 year with adaptive dose escalation comparing to standard treatment.</measure>
    <time_frame>at 1 year</time_frame>
    <description>18F-FDG-PET/CT scans will be performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional (elective neck) and distant control.</measure>
    <time_frame>after 1 year</time_frame>
    <description>18F-FDG-PET/CT scans will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topography of local and/or regional relapse.</measure>
    <time_frame>during the first year post-treatment</time_frame>
    <description>18F-FDG-PET/CT scans will be performed during the first year post-treatment time point of local and/or regional relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>3 months post-treatment</time_frame>
    <description>18F-FDG-PET/CT scans will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>up to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall disease-specific, disease-free survival.</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>up to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time point of local and/or regional relapse.</measure>
    <time_frame>during the first year post-treatment</time_frame>
    <description>18F-FDG-PET/CT scans will be performed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Primary Non-operated Squamous Cell Carcinoma of Oral Cavity</condition>
  <condition>Primary Non-operated Squamous Cell Carcinoma of Oropharynx</condition>
  <condition>Primary Non-operated Squamous Cell Carcinoma of Hypopharynx</condition>
  <condition>Primary Non-operated Squamous Cell Carcinoma of Larynx</condition>
  <arm_group>
    <arm_group_label>adaptive DPBN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This patient group will be treated by adaptive dose-painting-by-numbers, while patients in the control arm will receive standard treatment.&#xD;
Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard IMRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This patient group will be treated by standard intensity-modulated radiotherapy (IMRT), while patients in the experimental arm will receive adaptive dose-painting-by-numbers.&#xD;
Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adaptive dose-painting-by-numbers</intervention_name>
    <description>Adaptive dose escalation by dose-painting-by-numbers.</description>
    <arm_group_label>adaptive DPBN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard intensity-modulated radiotherapy (IMRT)</intervention_name>
    <description>Standard radiotherapy for head and neck cancer.</description>
    <arm_group_label>standard IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of oral cavity, oropharynx,&#xD;
             hypopharynx or larynx&#xD;
&#xD;
          -  Primary unresectable tumor and/or patients that refused surgery&#xD;
&#xD;
          -  Stages T1-4; T3-4 N0 or T(any) N1-3 for glottic cancer&#xD;
&#xD;
          -  Multidisciplinary decision of curative radiotherapy or radiochemotherapy&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 70 %&#xD;
&#xD;
          -  Age &gt;= 18 years old&#xD;
&#xD;
          -  Informed consent obtained, signed and dated before specific protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High risk Human Papilloma Virus (HPV)&#xD;
&#xD;
          -  Treatment combined with brachytherapy&#xD;
&#xD;
          -  Prior irradiation to the head and neck region&#xD;
&#xD;
          -  History of prior malignancies, except for cured non-melanoma skin cancer, curatively&#xD;
             treated in-situ carcinoma of the cervix or other cancer curatively treated and with no&#xD;
             evidence of disease for at least 5 years.&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Creatinine clearance (Cockcroft-Gault) =&lt; 60 mL/min&#xD;
&#xD;
          -  Mental condition rendering the patient unable to understand the nature, scope and&#xD;
             possible consequences of the study&#xD;
&#xD;
          -  Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikely to complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried De Neve, Ph.D., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Radiotherapy, University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique &amp; Materinit√© Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

